Nachrichten und Videos - PCM INC.

PCM Trials fait l'acquisition de Clinical Trial Service B.V., basée aux Pays Bas, devenant ainsi le fournisseur indépendant le plus expérimenté de services de visites mobiles avec la plus grande zone de couverture géographique à l'appui d'essais cliniques décentralisés PR Newswire DENVER, 10 janvier 2024 DENVER , 10 janvier 2024 /PRNewswire/ -- PCM Trials , un leader établi à Denver , aux États-Unis, qui fournit un personnel infirmier de recherche mobile pour les essais cliniques...

PCM Trials erwirbt die niederländische Clinical Trial Service B.V. und wird damit zum erfahrensten unabhängigen Anbieter von mobilen Besuchsdiensten mit dem größten geografischen Abdeckungsgebiet zur Unterstützung dezentraler klinischer Studien PR Newswire DENVER, 10. Januar 2024 DENVER , 10. Januar 2024 /PRNewswire/ -- PCM Trials , ein in Denver , USA , ansässiges führendes Unternehmen für die Bereitstellung von mobilen Forschungskrankenschwestern/-pflegern für dezentrale klinische...

PCM Trials Acquires Netherlands-Based Clinical Trial Service B.V., Becoming the Most Experienced Independent Provider of Mobile Visit Services with The Largest Geographic Coverage Area in Support of Decentralized Clinical Trials PR Newswire DENVER, Jan. 10, 2024 DENVER , Jan. 10, 2024 /PRNewswire/ -- PCM Trials , a Denver , USA -based leader in providing mobile research nurses for decentralized clinical trials (DCTs), today announced the acquisition of Clinical Trial Service (CTS). The Losser,...

PCM Trials adquiere Clinical Trial Service B.V., con sede en los Países Bajos PR Newswire DENVER, 10 de enero de 2024 -PCM Trials adquiere Clinical Trial Service B.V., con sede en los Países Bajos, y se convierte en el proveedor independiente más experimentado de servicios de visitas móviles con la mayor área de cobertura geográfica en apoyo de ensayos clínicos descentralizados DENVER , 10 de enero de 2024 /PRNewswire/ -- PCM Trials , un líder con sede en Denver , EE. UU. en el...

Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage PR Newswire SAN FRANCISCO, March 6, 2023 – Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO , March 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid...

Teresa Portela y Ray Zapata ya están en España tras haber conquistado la medalla de plata en los Juegos Olímpicos de Tokio. La piragüista, segunda en la ......

HH Global to acquire PCM and PMS PR Newswire ROTTERDAM, Netherlands, July 2, 2021 ROTTERDAM, Netherlands , July 2, 2021 /PRNewswire/ -- PaperChainManagement BV (PCM) and its sister company, PrintMediaServices BV (PMS), has been acquired by HH Global in a deal agreed on 30 June 2021 . Located in Haarlem, the Netherlands , PCM and PMS support both its domestic and international clients with procurement and supply chain optimisation services across print, POS and packaging. Existing PCM clients...

HH Global to acquire PCM and PMS PR Newswire ROTTERDAM, Netherlands, July 2, 2021 ROTTERDAM, Netherlands , July 2, 2021 /PRNewswire/ -- PaperChainManagement BV (PCM) and its sister company, PrintMediaServices BV (PMS), has been acquired by HH Global in a deal agreed on 30 June 2021 . Located in Haarlem, the Netherlands , PCM and PMS support both its domestic and international clients with procurement and supply chain optimisation services across print, POS and packaging. Existing PCM clients...

Catasys, Inc. (NASDAQ: CATS) (“Catasys” or the “Company”), a leading AI and telehealth enabled, virtualized outpatient healthcare treatment company, today announced the appointment of Mr. Brandon H. LaVerne as Chief Financial Officer. Mr. Terren Peizer, Chairman and CEO of Catasys, stated, “Catasys is rapidly scaling from being the leading healthcare engagement company at the intersection of behaviorial health and chronic disease into an advanced technology company with a portfolio of...

SHAREHOLDER ALERT: WeissLaw LLP Investigates PCM, Inc. Acquisition PR Newswire NEW YORK, June 24, 2019 NEW YORK , June 24, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of PCM, Inc. ("PCMI" or the "Company") (NASDAQ: PCMI) in connection with the proposed acquisition of the Company by Insight Enterprises ("Insight") (NASDAQ: NSIT). Under the terms of the agreement, PCMI shareholders will receive $35.00...

PCM (PMCI) Alert: Johnson Fistel Investigates Proposed Sale of PCM, Inc.; Are Shareholders Getting a Fair Price? PR Newswire SAN DIEGO, June 24, 2019 SAN DIEGO , June 24, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of PCM, Inc. (NASDAQ: PCMI) ("PCM") breached their fiduciary duties in connection with the proposed sale of the Company to Insight Enterprises. On June 24, 2019 , PCM announced that it had signed a...

Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe PR Newswire SAN DIEGO, Aug. 29, 2018 SAN DIEGO , Aug. 29, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs for the treatment of leukemias, lymphomas and solid tumor cancers, today announced that the European Commission (EC) has endorsed the positive...

Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the next dose level cohort of Onvansertib in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial PR Newswire SAN DIEGO, Aug. 16, 2018 SAN DIEGO , Aug. 16, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapies...

Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075 Onvansertib's product profile and attributes may offer the potential to provide significant clinical benefit with regard to efficacy and safety in patients with various types of cancer PR Newswire SAN DIEGO, Aug. 15, 2018 SAN DIEGO , Aug. 15, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company,...

Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug PR Newswire SAN DIEGO, Aug. 1, 2018 SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the treatment of leukemias/lymphomas and solid tumor cancers, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP)...

Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML Additional pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b/2 trial in Acute Myeloid Leukemia (AML) PR Newswire SAN DIEGO, June 27, 2018 SAN DIEGO , June 27, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage...

Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute and Massachusetts General Hospital officially activated and recruiting patients for Phase 2 open-label trial of PCM-075 and abiraterone acetate (Zytiga®) in metastatic Castration-Resistant Prostate Cancer (mCRPC) PR Newswire SAN DIEGO, June 21, 2018 SAN DIEGO , June 21, 2018...

Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with decitabine in dose-escalation phase of trial PR Newswire SAN DIEGO, June 15, 2018 SAN DIEGO , June 15, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics...

Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial PR Newswire SAN DIEGO, May 17, 2018 SAN DIEGO , May 17, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics for the...

Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b/2 Clinical Trial of PCM-075. Update on clinical trial recruitment. PR Newswire SAN DIEGO, April 17, 2018 SAN DIEGO , April 17, 2018 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a clinical-stage oncology therapeutics company, developing targeted therapeutics...